IMpower030: Atezolizumab Misses Primary Endpoint in NSCLC Megan Brooks September 15, 2026

https://www.medscape.com/viewarticle/impower030-atezolizumab-misses-primary-endpoint-nsclc-2026a1000y59?src= Adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival (EFS) in patients with stage IIB-IIIB resectable non-small cell lung cancer (NSCLC) without EGFR or ALK alterations, but the improvement did not reach statistical significance in the final analysis of the phase 3 IMpower030 trial.